Aurealis Therapeutics Overview

  • Status
  • Private

  • Employees
  • 18

Employees

  • Latest Deal Type
  • Series B
  • (Upcoming)

  • Latest Deal Amount
  • $40.9M

  • Investors
  • 11

Aurealis Therapeutics General Information

Description

Developer of a cell and gene therapy platform designed to heal multifactorial diseases. The company's platform facilitates a novel class of combination immunotherapy embedded in a single product that is efficient, scalable, and cost-effective, enabling medical professionals to get access to activate and modulate the innate immune system.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Baarerstrasse 21
  • 6300 Zug
  • Switzerland
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Baarerstrasse 21
  • 6300 Zug
  • Switzerland

Aurealis Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aurealis Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Later Stage VC (Series B) $40.9M Upcoming Clinical Trials - Phase 2
13. Later Stage VC 15-Nov-2024 Completed Clinical Trials - Phase 2
12. Later Stage VC (Series A) 30-Mar-2023 Completed Clinical Trials - Phase 2
11. Later Stage VC 01-Nov-2022 Completed Clinical Trials - Phase 2
10. Secondary Transaction - Private 01-Jan-2022 Completed Clinical Trials - Phase 2
9. Later Stage VC 14-Jun-2021 Completed Clinical Trials - Phase 1
8. Later Stage VC 21-Jan-2020 Completed Clinical Trials - Phase 1
7. Later Stage VC 05-Sep-2019 Completed Pre-Clinical Trials
6. Later Stage VC 08-Feb-2019 $7.85M $18M Completed Pre-Clinical Trials
5. Later Stage VC 24-May-2017 $5.66M $10.1M Completed Pre-Clinical Trials
To view Aurealis Therapeutics’s complete valuation and funding history, request access »

Aurealis Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary 104,800 $0.111261 $13.35 $13.35 1x $13.35 3.46%
Ordinary 357,814 $0.111261 $8.29 $8.29 1x $8.29 11.83%
To view Aurealis Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Aurealis Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a cell and gene therapy platform designed to heal multifactorial diseases. The company's platform facilitat
Drug Discovery
Zug, Switzerland
18 As of 2025

South San Francisco, CA
 

Philadelphia, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Aurealis Therapeutics Competitors (65)

One of Aurealis Therapeutics’s 65 competitors is CytomX Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Carisma Therapeutics Formerly VC-backed Philadelphia, PA
Ambrx Formerly PE-Backed San Diego, CA
Amphivena Therapeutics Venture Capital-Backed South San Francisco, CA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
You’re viewing 5 of 65 competitors. Get the full list »

Aurealis Therapeutics Patents

Aurealis Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2019433065-A1 Chloride-inducible prokaryotic expression system Active 04-Mar-2019
AU-2019433065-B2 Chloride-inducible prokaryotic expression system Active 04-Mar-2019
CA-3131796-A1 Chloride-inducible prokaryotic expression system Active 04-Mar-2019
CA-3131796-C Chloride-inducible prokaryotic expression system Active 04-Mar-2019
EP-3921422-A1 Chloride-inducible prokaryotic expression system Active 04-Mar-2019 C12N15/746
To view Aurealis Therapeutics’s complete patent history, request access »

Aurealis Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aurealis Therapeutics Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Lynx Financial Venture Capital Minority
Zhejiang Huahai Pharmaceutical Corporation Minority
Founders' Edge Venture Capital Minority
Tesi Limited Partner Minority
Connecticut Innovations Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

Aurealis Therapeutics FAQs

  • Where is Aurealis Therapeutics headquartered?

    Aurealis Therapeutics is headquartered in Zug, Switzerland.

  • What is the size of Aurealis Therapeutics?

    Aurealis Therapeutics has 18 total employees.

  • What industry is Aurealis Therapeutics in?

    Aurealis Therapeutics’s primary industry is Drug Discovery.

  • Is Aurealis Therapeutics a private or public company?

    Aurealis Therapeutics is a Private company.

  • What is Aurealis Therapeutics’s current revenue?

    The current revenue for Aurealis Therapeutics is .

  • How much funding has Aurealis Therapeutics raised over time?

    Aurealis Therapeutics has raised $40.3M.

  • Who are Aurealis Therapeutics’s investors?

    Lynx Financial, Zhejiang Huahai Pharmaceutical, Founders' Edge, Tesi, and Connecticut Innovations are 5 of 11 investors who have invested in Aurealis Therapeutics.

  • Who are Aurealis Therapeutics’s competitors?

    CytomX Therapeutics, Carisma Therapeutics, Ambrx, Amphivena Therapeutics, and Adaptimmune Therapeutics are some of the 65 competitors of Aurealis Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process